Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2426
Nordson
NDSN
$17.2B
| $1.45M | ﹤0.01% |
11,914
+2,400
| +25% | +$293K |
|
|
IRD
2427
Opus Genetics
IRD
$300M
| $1.45M | ﹤0.01% |
10,527
-1,470
| -12% | -$286K |
|
|
SOHO
2428
DELISTED
Sotherly Hotels
SOHO
| $1.44M | ﹤0.01% |
212,800
+13,900
| +7% | +$89.1K |
|
2429
Novavax
NVAX
$1.31B
| $1.43M | ﹤0.01% |
62,308
+46,865
| +303% | +$920K |
|
|
VCO
2430
DELISTED
Vina Concha Y Toro 50 Shrs
VCO
| $1.43M | ﹤0.01% |
46,200
+2,100
| +5% | +$67.6K |
|
2431
GoPro
GPRO
$110M
| $1.43M | ﹤0.01% |
+175,900
| New | +$1.49M |
|
2432
Flanigan's Enterprises
BDL
$87.4M
| $1.43M | ﹤0.01% |
47,200
+500
| +1% | +$12.9K |
|
2433
Compugen
CGEN
$227M
| $1.43M | ﹤0.01% |
375,100
-206,136
| -35% | -$857K |
|
|
HMNF
2434
DELISTED
HMN Financial Inc
HMNF
| $1.42M | ﹤0.01% |
80,700
+3,400
| +4% | +$59.9K |
|
|
EVBN
2435
DELISTED
Evans Bancorp Inc
EVBN
| $1.41M | ﹤0.01% |
35,400
+20,890
| +144% | +$812K |
|
|
DRNA
2436
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $1.41M | ﹤0.01% |
443,100
+24,600
| +6% | +$77.7K |
|
2437
StoneX
SNEX
$7.97B
| $1.4M | ﹤0.01% |
187,804
-294,637
| -61% | -$2.12M |
|
|
SIEN
2438
DELISTED
Sientra, Inc.
SIEN
| $1.4M | ﹤0.01% |
14,400
+11,740
| +441% | +$960K |
|
2439
ICL Group
ICL
$7.15B
| $1.4M | ﹤0.01% |
295,800
+54,200
| +22% | +$234K |
|
2440
Innovative Solutions & Support
ISSC
$419M
| $1.39M | ﹤0.01% |
316,300
-9,000
| -3% | -$32.6K |
|
|
DBD
2441
DELISTED
Diebold Nixdorf Incorporated
DBD
| $1.39M | ﹤0.01% |
+49,700
| New | +$1.37M |
|
|
STKL
2442
DELISTED
SunOpta
STKL
| $1.39M | ﹤0.01% |
+136,297
| New | +$1.14M |
|
|
TRIB
2443
Trinity Biotech
TRIB
$8.17M
| $1.39M | ﹤0.01% |
1,540
+442
| +40% | +$376K |
|
|
EBIX
2444
DELISTED
Ebix Inc
EBIX
| $1.38M | ﹤0.01% |
25,580
+5,700
| +29% | +$328K |
|
|
NMRX
2445
DELISTED
Numerex Corp
NMRX
| $1.38M | ﹤0.01% |
279,800
+21,200
| +8% | +$94.5K |
|
2446
SPS Commerce
SPSC
$2.82B
| $1.38M | ﹤0.01% |
43,200
-58,600
| -58% | -$1.74M |
|
2447
Costamare
CMRE
$1.75B
| $1.38M | ﹤0.01% |
188,300
+161,429
| +601% | +$1.13M |
|
|
BDSI
2448
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $1.37M | ﹤0.01% |
490,700
+337,900
| +221% | +$713K |
|
2449
PDF Solutions
PDFS
$2.15B
| $1.37M | ﹤0.01% |
83,400
-85,700
| -51% | -$1.59M |
|
2450
Gorman-Rupp
GRC
$2.13B
| $1.37M | ﹤0.01% |
53,715
+7,915
| +17% | +$212K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.